INS and Hypoglycemia: In addition to the effects of exendin-(9-39) on baseline islet cAMP and insulin secretion, exendin-(9-39) inhibited amino acid-stimulated insulin secretion, a key phenotypic feature of hyperinsulinism due to inactivating mutations in the KATP channels where consumption of protein leads to insulin secretion and hypoglycemia (30, 31).